Login / Signup

Randomized Phase III KEYNOTE-181 Study of Pembrolizumab Versus Chemotherapy in Advanced Esophageal Cancer.

Takashi KojimaManish A ShahKei MuroEric FrancoisAntoine AdenisChih-Hung HsuToshihiko DoiToshikazu MoriwakiSung-Bae KimSe-Hoon LeeJaafar BennounaKen KatoLin ShenPeter EnzingerShu-Kui QinPaula FerreiraJia ChenGustavo C GirottoChristelle De La FouchardièreHelene SenellartRaed Al-RajabiFlorian LordickRuixue WangShailaja SuryawanshiPooja BhagiaS Peter KangJean-Philippe Metgesnull null
Published in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2020)
Pembrolizumab prolonged OS versus chemotherapy as second-line therapy for advanced esophageal cancer in patients with PD-L1 CPS ≥ 10, with fewer treatment-related adverse events.
Keyphrases
  • phase iii
  • open label
  • phase ii
  • double blind
  • clinical trial
  • placebo controlled
  • locally advanced
  • advanced non small cell lung cancer
  • squamous cell carcinoma
  • radiation therapy
  • randomized controlled trial